MLK Memorial, Washington DC

We’re continuing our previews of the forthcoming 2017 annual meeting of the American Association for Cancer Research (AACR) in Washington DC with a look at an emerging pathway that may impact checkpoint therapy.

It’s an exciting time in cancer immunotherapy, although only a small minority of people have remarkable long-term durable responses and the reality is that most patients, even if they respond initially, end up relapsing at some point.

There’s still a lot to learn about cancer immunotherapy – we’re just scratching the surface of what’s possible.

At AACR17 we can expect to see insights on the direction the field is going. In this post we take a look at an emerging pathway, and some of the key presentations and posters that you should see if you are in DC for the meeting.

Subscribers can login to read more

Posted by